Central Fatigue: What Could Be Causing It

What Central Fatigue Actually Means

Central fatigue is the brain's inability to sustain the neural drive required for voluntary movement or prolonged cognitive tasks. Unlike peripheral fatigue, where muscles fail because of local metabolic depletion, central fatigue reflects dysfunction upstream in the motor cortex, basal ganglia, or descending corticospinal pathways [1]. The distinction matters because the diagnostic approach and treatment differ completely.

The concept was formalized in exercise physiology research during the 1980s and 1990s, with Newsholme and colleagues proposing the "central fatigue hypothesis" based on serotonin accumulation during prolonged exercise [2]. Since then, the term has expanded well beyond sports science. Clinicians now apply it to the persistent, disproportionate exhaustion seen in multiple sclerosis, post-stroke patients, endocrine disorders, and chronic inflammatory states.

A 2023 systematic review in The Lancet Neurology estimated that central mechanisms account for fatigue complaints in 40% to 60% of patients with neurological disease, though the true prevalence in general primary care remains harder to pin down [3]. The challenge is that patients describe central and peripheral fatigue identically: "I'm exhausted." Separating them requires understanding the neurobiology and running the right tests.

The Serotonin-Dopamine Imbalance Theory

The most studied neurochemical explanation involves the ratio between serotonin (5-HT) and dopamine in the brain. Elevated serotonin activity in the dorsal raphe nucleus suppresses motor output. Simultaneously, dopamine depletion in the ventral tegmental area and substantia nigra reduces motivation and reward signaling [4]. The net effect is a person who feels unable to start or sustain effort.

This is not speculation. Meeusen and Roelands published a landmark review in Medicine & Science in Sports & Exercise (2018) demonstrating that pharmacological manipulation of the 5-HT/dopamine ratio altered time-to-exhaustion in controlled human trials [4]. Subjects given a selective serotonin reuptake inhibitor (SSRI) during exercise fatigued faster, while those given a dopamine reuptake inhibitor (bupropion) maintained output longer.

The clinical relevance extends to patients on SSRIs who report new-onset fatigue after starting medication. A 2019 analysis in the Journal of Clinical Psychiatry (N=665) found that 38% of SSRI-treated patients reported persistent fatigue as a side effect at 8 weeks, even when depression scores improved [5]. When a patient on sertraline or fluoxetine reports worsening tiredness despite better mood, central serotonergic fatigue should be considered before adding stimulants.

Endocrine Causes: Thyroid, Testosterone, Cortisol

Hormonal deficiencies are among the most treatable causes of central fatigue. The hypothalamus and pituitary sit at the intersection of endocrine regulation and arousal, so dysfunction in either gland creates fatigue that is unquestionably central in origin.

Hypothyroidism affects roughly 5% of the U.S. adult population, and fatigue is the presenting symptom in over 80% of cases [6]. The mechanism is straightforward: thyroid hormone modulates cerebral metabolic rate. A TSH above 10 mIU/L with low free T4 confirms overt disease, but subclinical hypothyroidism (TSH 4.5 to 10, normal free T4) also produces measurable fatigue. The 2023 American Thyroid Association guidelines recommend treating subclinical disease when TSH exceeds 7 mIU/L and symptoms are present [6].

Hypogonadism is underdiagnosed in both sexes. In men, the Endocrine Society defines testosterone deficiency as a total testosterone below 300 ng/dL on two morning draws paired with symptoms [7]. Fatigue, reduced motivation, and cognitive slowing are cardinal features. The TRAVERSE trial (N=5,246) confirmed that testosterone replacement in hypogonadal men improved energy scores on the SF-36 vitality domain by 4.2 points versus placebo at 12 months [8]. Women in perimenopause and menopause experience analogous declines in estradiol and progesterone that correlate with fatigue severity, per a 2022 Menopause journal analysis [9].

Adrenal insufficiency, whether primary (Addison disease) or secondary (from chronic exogenous glucocorticoid use or pituitary pathology), produces fatigue that patients describe as "bone-deep." Morning cortisol below 3 mcg/dL is strongly suggestive; a cosyntropin stimulation test confirms the diagnosis [10].

Neurological Conditions That Drive Central Fatigue

Several neurological diseases produce fatigue that is central by definition, because the pathology sits within the CNS itself.

Multiple sclerosis (MS) is the prototypical example. Between 75% and 95% of MS patients report fatigue as their most disabling symptom, and roughly 50% rank it as their single worst complaint [11]. MS-related fatigue correlates with lesion burden in the cortico-striato-thalamo-cortical loop on MRI, and functional imaging shows reduced activation of the supplementary motor area during sustained tasks. Dr. Lauren Krupp, who developed the Fatigue Severity Scale at NYU Langone, has stated: "Fatigue in MS is not laziness or deconditioning. It is a direct consequence of demyelination disrupting the circuits that sustain effort" [11].

Parkinson disease produces central fatigue in 50% to 70% of patients, separate from motor slowness [12]. Dopaminergic degeneration in the substantia nigra directly impairs the motivation-to-effort pathway. Levodopa partially alleviates motor fatigue but often leaves cognitive fatigue untouched, supporting a non-dopaminergic component involving norepinephrine and orexin.

Post-stroke fatigue affects 25% to 85% of stroke survivors depending on the study and time point measured [13]. A 2021 meta-analysis in Stroke (38 studies, N=10,672) found a pooled prevalence of 50% at 1 year post-event [13]. Fatigue severity correlated with lesion location in the basal ganglia and brainstem reticular activating system, not with stroke size alone.

Traumatic brain injury (TBI), even mild concussion, produces central fatigue that can persist for months. The mechanism involves diffuse axonal injury disrupting arousal pathways from the reticular formation to the thalamus and cortex [14].

Chronic Fatigue Syndrome and Post-Viral Fatigue

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is the most debated central fatigue condition. The 2015 Institute of Medicine (now National Academy of Medicine) report renamed it "systemic exertion intolerance disease" and proposed diagnostic criteria requiring fatigue lasting more than 6 months, post-exertional malaise, and unrefreshing sleep [15].

The post-COVID era added millions of new cases. A 2023 Nature Reviews Neuroscience review estimated that 10% to 30% of COVID-19 survivors develop persistent fatigue meeting ME/CFS-like criteria at 12 months [16]. Dr. Anthony Komaroff of Harvard Medical School, one of the leading ME/CFS researchers, wrote in JAMA (2023): "Post-infectious central fatigue is real, measurable with neuroimaging, and associated with chronic neuroinflammation involving activated microglia in the brainstem and thalamus" [16].

Neuroimaging studies using PET with the translocator protein (TSPO) ligand [11C]PBR28 have shown increased microglial activation in the cingulate cortex, thalamus, and midbrain of ME/CFS patients compared to healthy controls (P<0.01) [17]. This is not "all in the head" in the dismissive sense. It is, quite literally, in the brain, and it can be photographed.

Psychiatric and Sleep-Related Central Fatigue

Major depressive disorder (MDD) produces central fatigue through overlapping serotonergic, noradrenergic, and inflammatory mechanisms. The STAR*D trial (N=4,041) documented that 73% of untreated MDD patients reported fatigue as a presenting symptom, and fatigue was one of the last symptoms to resolve with treatment [18]. Even after remission of mood symptoms, residual fatigue persisted in 22% to 38% of patients across all treatment arms.

Sleep disorders are a correctable cause that must be excluded early. Obstructive sleep apnea (OSA) fragments sleep architecture, reducing time in slow-wave and REM stages that are required for CNS restoration. A 2020 American Journal of Respiratory and Critical Care Medicine study found that CPAP adherence of 4 or more hours per night improved Epworth Sleepiness Scale scores by a mean of 4.75 points (95% CI: 3.89 to 5.61) compared to sham CPAP [19]. Insomnia disorder, restless legs syndrome, and circadian rhythm disorders should also be screened.

Anxiety disorders, particularly generalized anxiety disorder (GAD), produce fatigue through chronic autonomic hyperactivation and sleep disruption. The DSM-5-TR lists fatigue as a diagnostic criterion for GAD. Clinicians sometimes overlook this because anxiety "seems like the opposite of fatigue," but sustained sympathetic overdrive depletes norepinephrine reserves over weeks to months.

Metabolic and Nutritional Contributors

Iron deficiency remains the most common nutritional cause of central fatigue worldwide. Ferritin below 30 ng/mL (not just below the lab reference range of 10 to 15) is associated with fatigue even in the absence of frank anemia [20]. The mechanism involves iron's role as a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. Low brain iron means low dopamine production. A 2020 Cochrane review (24 RCTs, N=4,785) concluded that iron supplementation reduced fatigue severity in iron-deficient non-anemic women with a standardized mean difference of 0.34 (95% CI: 0.13 to 0.55) [20].

Vitamin D deficiency (25-OH-D below 20 ng/mL) correlates with fatigue severity in multiple large cohort studies, though causality is debated. A 2019 meta-analysis in Medicine (12 RCTs, N=1,137) found that vitamin D supplementation significantly reduced fatigue scores versus placebo when baseline levels were below 20 ng/mL [21].

Poorly controlled type 2 diabetes produces central fatigue through both direct CNS glucotoxicity and chronic systemic inflammation. HbA1c above 8.0% correlates with worse cognitive fatigue scores independent of depression [22]. Insulin resistance itself may impair hypothalamic energy sensing.

Chronic kidney disease (CKD) and liver disease produce central fatigue through uremic toxin accumulation and hepatic encephalopathy respectively. Both should be considered when the basic metabolic panel or hepatic function panel is abnormal.

The Diagnostic Workup: What to Order and Why

The first-line laboratory panel for undifferentiated central fatigue should include the following, drawn fasting and before 10 AM for cortisol and testosterone accuracy:

• CBC with differential (anemia, infection, hematologic malignancy)
• CMP (renal function, hepatic function, glucose, electrolytes)
• TSH and free T4 (thyroid disease)
• Total testosterone, free testosterone, SHBG (hypogonadism, drawn before 10 AM)
• Morning cortisol (adrenal insufficiency)
• Ferritin (iron deficiency; target above 30 ng/mL for symptom relevance)
• 25-hydroxyvitamin D (deficiency below 20 ng/mL)
• HbA1c (diabetes screening)
• CRP or ESR (systemic inflammation)
• Urinalysis (renal screening)

If first-line labs are unrevealing, second-tier testing includes: ANA, anti-dsDNA (autoimmune disease), Epstein-Barr virus panel (reactivation), Lyme antibody with Western blot (endemic areas), overnight oximetry or polysomnography (sleep apnea), and brain MRI with gadolinium (MS, structural lesions) [23].

The ordering matters. Do not send a patient for an MRI before checking their ferritin. Fix the cheap, common things first. As the BMJ Best Practice guideline on chronic fatigue (2024) states: "A structured, stepwise approach prevents both under-investigation of serious pathology and over-investigation that increases patient anxiety" [23].

Treatment Approaches by Etiology

No single drug treats central fatigue. Treatment follows the cause.

For hypothyroidism, levothyroxine titrated to a TSH of 0.5 to 2.5 mIU/L resolves fatigue in the majority of patients within 6 to 12 weeks [6]. For hypogonadism in men, testosterone cypionate 100 to 200 mg intramuscularly every 1 to 2 weeks or transdermal testosterone 50 mg daily are first-line, per Endocrine Society guidelines [7]. For iron deficiency, oral ferrous sulfate 325 mg every other day (better absorbed than daily dosing per a 2017 The Lancet Haematology RCT) or IV iron for malabsorption or intolerance [20].

For MS-related fatigue, amantadine 100 mg twice daily is the most commonly prescribed agent, though evidence is modest. Modafinil 200 mg daily has shown benefit in small trials but remains off-label [11]. Exercise prescription (aerobic, 30 minutes, 3 times per week) carries Grade A evidence for MS fatigue reduction.

For depression-related fatigue, bupropion (a norepinephrine-dopamine reuptake inhibitor) is preferred over SSRIs when fatigue is a dominant symptom, because it avoids serotonergic fatigue exacerbation [5]. The 2023 APA Practice Guidelines acknowledge bupropion's relative advantage for the "fatigue-predominant" MDD phenotype [18].

For ME/CFS and post-viral fatigue, pacing (activity management) is the only intervention with consistent evidence. Graded exercise therapy, once recommended by the 2011 NICE guidelines, was removed in the 2021 update after re-analysis showed potential harm in a subgroup of patients [15]. Low-dose naltrexone (1.5 to 4.5 mg at bedtime) is under investigation, with a 2022 pilot RCT (N=52) showing improved fatigue scores versus placebo, but it remains experimental [15].

For sleep apnea, CPAP at therapeutic pressures (typically 6 to 14 cm H2O) with a minimum adherence of 4 hours per night is the standard of care [19]. Oral appliances or hypoglossal nerve stimulation (Inspire device) are alternatives when CPAP is not tolerated.

When to Refer Beyond Primary Care

Refer to endocrinology if the hormonal picture is complex (concurrent thyroid and adrenal abnormalities, suspected pituitary pathology, or testosterone replacement in women). Refer to neurology if the exam reveals focal deficits, the MRI is abnormal, or fatigue follows a pattern consistent with MS, Parkinson disease, or post-concussive syndrome. Refer to sleep medicine when the Epworth Sleepiness Scale is 10 or higher or overnight oximetry shows an oxygen desaturation index above 5 events per hour. Refer to psychiatry when depression or anxiety is severe, suicidal ideation is present, or first-line antidepressant trials have failed.

Patients with fatigue lasting more than 6 months despite normal labs and absence of psychiatric diagnosis should be evaluated for ME/CFS using the 2015 National Academy of Medicine criteria: fatigue reducing activity by more than 50%, post-exertional malaise, unrefreshing sleep, plus either cognitive impairment or orthostatic intolerance [15].

The single most important clinical instruction: draw the labs before attributing central fatigue to stress, deconditioning, or "just getting older." A ferritin of 12, a TSH of 14, or a testosterone of 180 ng/dL changes the entire treatment trajectory, and all three are fixable.